Company Overview and News

AINC / Ashford Inc. - Stock Institutional Ownership and Shareholders -

Ashford Inc. (AMEX:AINC) has 35 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 926,102 shares. Largest shareholders include Ashford Hospitality Trust Inc, Raging Capital Management, LLC, Vanguard Group Inc, BlackRock Inc., Russell Investments Group, Ltd., Snow Park Capital Partners, Lp, Geode Capital Management, Llc, Renaissance Technologies LLC, Northern Trust Corp, and Bridgeway Capital Management Inc.
Upvote Downvote

Top Analyst Reports for Goldman Sachs, Abbott & Altria

19h zacks
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Goldman Sachs (GS), Abbott Labs (ABT) and Altria (MO). These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
Upvote Downvote

BSF / Bear State Financial, Inc. - Stock Institutional Ownership and Shareholders -

Bear State Financial, Inc. (NASDAQ:BSF) has 72 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 4,970,821 shares. Largest shareholders include BlackRock Inc., Horrell Capital Management, Inc., Vanguard Group Inc, Dimensional Fund Advisors Lp, Stephens Inc /ar/, Renaissance Technologies LLC, State Street Corp, Northern Trust Corp, Gabelli Funds Llc, and Deutsche Bank Ag\.
Upvote Downvote

5 Top Earnings Growth Stocks for a Winning Portfolio

2018-04-20 zacks
As we have entered the Q1 reporting cycle, seasoned investors will be on the lookout for stocks with steadfast earnings growth. After all, if the company doesn’t make money, it won’t last over the long haul. Consider a company’s revenues over a stipulated time frame, subtract the cost of production and you have earnings.
Upvote Downvote

ZTE woes may boost network rivals Ericsson and Nokia - Channel NewsAsia

2018-04-19 channelnewsasia
Investors are warming to beleaguered mobile network makers Ericsson and Nokia as they begin to recover ahead of a once-a-decade uplift from a new business cycle and an unexpected boost from a U.S. ban on exports to low-cost Chinese rival ZTE.
Upvote Downvote

ZTE woes may boost network rivals Ericsson and Nokia

2018-04-19 reuters
STOCKHOLM/LONDON (Reuters) - Investors are warming to beleaguered mobile network makers Ericsson and Nokia as they begin to recover ahead of a once-a-decade uplift from a new business cycle and an unexpected boost from a U.S. ban on exports to low-cost Chinese rival ZTE.
Upvote Downvote

BancorpSouth's (BXS) Q1 Earnings Beat Estimates, Costs Rise

2018-04-19 zacks
BancorpSouth (BXS - Free Report) reported first-quarter 2018 operating earnings of 54 cents per share, beating the Zacks Consensus Estimate of 50 cents. Also, the bottom line compared favorably with the year-ago quarter earnings of 41 cents. Results benefitted from an improvement in net interest revenues and non-interest revenues, partially offset by higher expenses. Loans and deposit balances remained strong during the quarter.
Upvote Downvote

Snap-On's stock climbs 2.3% premarket after Q1 results

2018-04-19 marketwatch
Snap-on Inc. SNA said Thursday that first-quarter net income rose 15%, in part due to the tax overhaul in the U.S. The Wisconsin-based maker of automotive tools, diagnostic equipment, and software earned a quarterly profit of $163 million, or $2.82 a share, compared with $141.6 million, or $2.39 a share, for the same period a year earlier.
Upvote Downvote

BNY Mellon, Under Investor Pressure, Posts 9% Revenue Growth - Bloomberg

2018-04-19 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
Upvote Downvote

Venezuela bondholders inch toward $50 billion debt default showdown | Reuters

2018-04-18 reuters
LONDON/CARACAS (Reuters) - Investors holding billions of dollars in defaulted Venezuelan bonds have formed at least one bondholder committee that is seeking a financial adviser, according to several sources familiar with the matter, in a sign they may be gearing up for a legal dispute.
Upvote Downvote

U.S. Bancorp's (USB) Q1 Earnings Beat Estimates, Revenues Up

2018-04-18 zacks
U.S. Bancorp’s (USB - Free Report) first-quarter 2018 adjusted earnings per share of 95 cents surpassed the Zacks Consensus Estimate by a penny. The figure came ahead of the prior-year quarter earnings of 82 cents. The company’s top line benefitted from rise in net interest income on the back of easing margin pressure and higher fee income. Further, elevated average loans and deposit balances were tailwinds.
Upvote Downvote

Northern Trust's (NTRS) Management on Q1 2018 Results - Earnings Call Transcript

2018-04-17 seekingalpha
Ladies and gentlemen, thank you for standing by. Good day, and welcome to the Northern Trust Corporation First Quarter 2018 Earnings Conference Call. Today's call is being recorded.
Upvote Downvote

Northern Trust Corporation 2018 Q1 - Results - Earnings Call Slides

2018-04-17 seekingalpha
The following slide deck was published by Northern Trust Corporation in conjunction with their 2018 Q1 earnings call.
Upvote Downvote

Related Articles

RDHL: Redhill Biopharma Ltd (OTC:REDIF) Analysis and Research Report

2018-04-18 - Asif

History and Development of the Company The company's legal and commercial name is RedHill Biopharma Ltd. The company's company was incorporated on August 3, 2009, and was registered as a private company limited by shares under the laws of the State of Israel. The company's principal executive offices are located at 21 Ha’arba’a Street, Tel Aviv, Israel. In February 2011, the company completed its initial public offering in Israel, pursuant to which the company issued 14,302,300 Ordinary Shares, and 7,151,150 tradable Series 1 Warrants to purchase 7,151,150 Ordinary Shares for aggregate gross proceeds of approximately $14 million. On December 27, 2012, the company completed the listing of its ADSs on the NASDAQ Capital Market. The company's Ordinary Shares are traded on the Tel-Aviv Stock Exchange under the symbol “RDHL,” and its ADSs are traded on the NASDAQ Capital Market under the same symbol "RDHL". The company's capital expenditures for the years ended December 31, 2...

SCYX: SCYNEXIS Analysis and Research Report

2018-04-16 - Asif

Overview SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS is developing its lead product candidate, SCY-078, as the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis (VVC). SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo against a broad range of human fungi pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in t...

ENRT: Enertopia Corp (CNSX:TOP) Analysis and Research Report

2018-04-16 - Asif

Business History Enertopia Corp. was formed on November 24, 2004 under the laws of the State of Nevada and commenced operations on November 24, 2004. From inception until April 2010, the company were primarily engaged in the acquisition and exploration of natural resource properties. Beginning in April 2010, the company began its entry into the renewable energy sector by purchasing an interest in a solar thermal design and installation company. In late summer 2013, the company began its entry into medicinal marijuana business. During its 2014 fiscal year end its activities in the clean energy sector were discontinued. During fiscal 2015 its activities in the Medicinal Marijuana sector were discontinued. During fiscal 2016 its activities in the Women’s personal healthcare sector were discontinued. The Company is actively pursuing business opportunities in the resource sector, whereby the company signed a definitive agreement for a Lithium Brine Project in May 2016. In May ...

FB: Facebook Analysis and Research Report

2018-04-15 - Asif

Overview The company's mission is to give people the power to build community and bring the world closer together. The company's top priority is to build useful and engaging products that enable people to connect and share with friends and family through mobile devices, personal computers, and other surfaces. The company also help people discover and learn about what is going on in the world around them, enable people to share their opinions, ideas, photos and videos, and other activities with audiences ranging from their closest friends to the public at large, and stay connected everywhere by accessing its products, including: Facebook enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers. There are a number of different ways to engage with people on Facebook, the most important of which is News Feed which displays an algorithmically-ranked series of stories and advertisements individualized for each pers...

VSTM: Verastem Analysis and Research Report

2018-04-12 - Asif

Business Overview Verastem is a biopharmaceutical company focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients. The company's most advanced product candidates, duvelisib and defactinib, utilize a multi-faceted approach to treat cancers originating either in the blood or major organ systems. Verastem is currently evaluating these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including leukemia, lymphoma, lung cancer, ovarian cancer, mesothelioma, and pancreatic cancer. The company believe that these compounds may be beneficial as therapeutics either as single agents or when used in combination with immuno-oncology agents or other current and emerging standard of care treatments in aggressive cancers that are poorly served by currently available therapies. Duvelisib targets the Phosphoinositide 3-kinase (PI3K) signaling pathway. The PI3K signaling pathway plays a centr...